JP2025503511A5 - - Google Patents
Info
- Publication number
- JP2025503511A5 JP2025503511A5 JP2024538652A JP2024538652A JP2025503511A5 JP 2025503511 A5 JP2025503511 A5 JP 2025503511A5 JP 2024538652 A JP2024538652 A JP 2024538652A JP 2024538652 A JP2024538652 A JP 2024538652A JP 2025503511 A5 JP2025503511 A5 JP 2025503511A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- product according
- her2
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163294367P | 2021-12-28 | 2021-12-28 | |
| US63/294,367 | 2021-12-28 | ||
| PCT/IB2022/062797 WO2023126822A1 (en) | 2021-12-28 | 2022-12-27 | Combination of antibody-drug conjugate and rasg12c inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503511A JP2025503511A (ja) | 2025-02-04 |
| JP2025503511A5 true JP2025503511A5 (enExample) | 2026-01-05 |
Family
ID=84943594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538652A Pending JP2025503511A (ja) | 2021-12-28 | 2022-12-27 | 抗体－薬物コンジュゲート及びｒａｓｇ１２ｃ阻害剤の組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250161305A1 (enExample) |
| EP (1) | EP4456899A1 (enExample) |
| JP (1) | JP2025503511A (enExample) |
| CN (1) | CN118434422A (enExample) |
| TW (1) | TW202333800A (enExample) |
| WO (1) | WO2023126822A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026124488A1 (zh) * | 2024-12-10 | 2026-06-18 | 正大天晴药业集团股份有限公司 | 抗her2抗体药物偶联物或其联用药物治疗非小细胞肺癌的用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP0699754B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Method for diagnosing a predisposition for breast and ovarian cancer |
| DE69521002T3 (de) | 1994-08-12 | 2010-02-25 | The University Of Utah Research Foundation, Salt Lake City | Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| JP6282232B2 (ja) | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド，ボルティモア | 抗体及びそのＦｃフラグメントの酵素化学的糖鎖改変 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| CA3082579A1 (en) | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| ES3010507T3 (en) | 2019-03-05 | 2025-04-03 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| CR20220258A (es) | 2019-12-11 | 2022-07-03 | Lilly Co Eli | Inhibidores de kras g12c |
| CN116034106B (zh) | 2020-06-02 | 2025-11-04 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
-
2022
- 2022-12-27 JP JP2024538652A patent/JP2025503511A/ja active Pending
- 2022-12-27 US US18/724,593 patent/US20250161305A1/en active Pending
- 2022-12-27 EP EP22843394.2A patent/EP4456899A1/en active Pending
- 2022-12-27 TW TW111150125A patent/TW202333800A/zh unknown
- 2022-12-27 CN CN202280084640.8A patent/CN118434422A/zh active Pending
- 2022-12-27 WO PCT/IB2022/062797 patent/WO2023126822A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539715A5 (enExample) | ||
| JP2023542066A5 (enExample) | ||
| JP2025041725A5 (enExample) | ||
| JPWO2020122034A5 (enExample) | ||
| JP2023545096A5 (enExample) | ||
| JP2023070678A5 (enExample) | ||
| JPWO2020130125A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2010535713A5 (enExample) | ||
| FI4516357T3 (fi) | Kasvaimen kasvua estävä yhdiste ja menetelmä sen valmistamiseksi ja sen käyttö | |
| JP2020019787A5 (enExample) | ||
| JP2024075668A (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP2008500815A5 (enExample) | ||
| JP2019031565A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2018525354A5 (enExample) | ||
| CN106999606A (zh) | 抗体药物偶联物 | |
| JP2020526584A5 (enExample) | ||
| JP2025507817A5 (enExample) | ||
| JP2024546605A5 (enExample) | ||
| JP2025509266A5 (enExample) | ||
| JP2024536881A5 (enExample) | ||
| JP2020534300A5 (enExample) | ||
| JP2023542065A5 (enExample) | ||
| JP2019524713A5 (enExample) |